Omeros Corporation (NASDAQ: OMER) shares plunged 12.14% as profit-taking and investor caution follow FDA approval and Novo Nordisk deal.

Omeros Corporation (NASDAQ: OMER) shares plunged 12.1429% in pre-market trading on January 7, 2026, marking a sharp reversal from recent gains tied to regulatory approvals and strategic partnerships. The selloff follows a volatile trading pattern in late 2025, where the stock initially surged on FDA clearance for its TA-TMA treatment YARTEMLEA® and a $340 million licensing deal with Novo Nordisk for an immune-system drug.

Analysts suggest the decline reflects profit-taking and investor caution after months of aggressive price movements. While the FDA approval in December 2025 positioned Omeros as a key player in a niche transplant therapy market, the stock’s rapid ascent may have created short-term overvaluation. Meanwhile, the Novo Nordisk partnership, though a significant milestone, has shifted focus away from Omeros’ core product pipeline, raising questions about its long-term growth trajectory.

Market sentiment remains mixed, with brokerages maintaining "buy" ratings but highlighting near-term volatility risks. The drop underscores the sector’s sensitivity to clinical and partnership developments, as investors weigh near-term cash flows against unproven therapeutic potential in Omeros’ broader portfolio.

Analysts also point to broader sector trends and regulatory timelines that could influence Omeros’ stock trajectory in the coming months. While the company's recent partnerships have provided immediate financial benefits, long-term success will depend on the performance of its clinical trials and the commercialization of its pipeline. Investors are advised to monitor upcoming FDA milestones and quarterly revenue reports closely as these could serve as potential turning points.